Today, the first domestic COVID-19 vaccine is on the market with conditions.

On December 31, the joint prevention and control mechanism of the State Council released that Sinopharm China covid-19 inactivated vaccine has been approved by the State Food and Drug Administration for conditional listing. Existing data show that the protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, and meeting the relevant standards of the World Health Organization and the State Food and drug administration. In the follow-up, the persistence and protective effect of vaccine immunization need to be continuously observed. This achievement was not easy to come by. The launch of China's vaccine injected confidence into the global fight against the epidemic, and also provided strong support for the vaccine to become a global public product